{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:38:31Z","timestamp":1790890711874,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T00:00:00Z","timestamp":1588896000000},"content-version":"am","delay-in-days":342,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.autrev.2018.12.008","type":"journal-article","created":{"date-parts":[[2019,4,6]],"date-time":"2019-04-06T00:12:50Z","timestamp":1554509570000},"page":"576-582","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["The pipeline of targeted therapies under clinical development for primary Sj\u00f6gren's syndrome: A systematic review of trials"],"prefix":"10.1016","volume":"18","author":[{"given":"Renaud","family":"Felten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Scher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Sibilia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques-Eric","family":"Gottenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Arnaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9\u201316","key":"10.1016\/j.autrev.2018.12.008_bb0005","article-title":"American college of rheumatology\/European league against rheumatism classification criteria for primary Sj\u00f6gren's syndrome: a consensus and data-driven methodology involving three international patient cohorts","volume":"76","author":"Shiboski","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2018.12.008_bb0010","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1136\/annrheumdis-2014-205375","article-title":"Epidemiology of primary Sj\u00f6gren's syndrome: a systematic review and meta-analysis","volume":"74","author":"Qin","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"142\u201354","key":"10.1016\/j.autrev.2018.12.008_bb0015","article-title":"NK cells in autoimmune diseases: linking innate and adaptive immune responses","volume":"17","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2018.12.008_bb0020","first-page":"1267","article-title":"Sex steroid hormones in primary Sj\u00f6gren's syndrome","volume":"30","author":"Brennan","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2018.12.008_bb0025","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jaut.2014.02.008","article-title":"Infection and autoimmunity in Sjogren's syndrome: a clinical study and comprehensive review","volume":"51","author":"Kivity","year":"2014","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2018.12.008_bb0030","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1038\/ng.2792","article-title":"Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sj\u00f6gren's syndrome","volume":"45","author":"Lessard","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.autrev.2018.12.008_bb0035","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.autrev.2012.10.006","article-title":"Type I interferons in Sj\u00f6gren's syndrome","volume":"12","author":"Yao","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2018.12.008_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2018.02.003","article-title":"Cytokine markers of B lymphocytes in minor salivary gland infiltrates in Sj\u00f6gren's syndrome","author":"Navarro-Mendoza","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2018.12.008_bb0045","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.autrev.2017.11.009","article-title":"Targeting interferons and their pathways in systemic lupus erythematosus","volume":"17","author":"Chasset","year":"2018","journal-title":"Autoimmun Rev"},{"issue":"8","key":"10.1016\/j.autrev.2018.12.008_bb0050","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.autrev.2018.02.011","article-title":"The 2018 pipeline of targeted therapies under clinical development for systemic lupus Erythematosus: a systematic review of trials","volume":"17","author":"Felten","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2018.12.008_bb0055","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1136\/ard.2007.083865","article-title":"Reduction of fatigue in Sj\u00f6gren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study","volume":"67","author":"Dass","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2018.12.008_bb0060","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/art.27314","article-title":"Effectiveness of rituximab treatment in primary Sj\u00f6gren's syndrome: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Meijer","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"233\u201342","key":"10.1016\/j.autrev.2018.12.008_bb0065","article-title":"Treatment of primary Sj\u00f6gren syndrome with rituximab: a randomized trial","volume":"160","author":"Devauchelle-Pensec","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2018.12.008_bb0070","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/art.40093","article-title":"Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and Oral dryness in primary Sj\u00f6gren's syndrome","volume":"69","author":"Bowman","year":"2017","journal-title":"Arthritis Rheum Hoboken NJ"},{"key":"10.1016\/j.autrev.2018.12.008_bb0075","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1136\/annrheumdis-2012-202293","article-title":"Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and rituximab registry","volume":"72","author":"Gottenberg","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2018.12.008_bb0080","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.autrev.2017.07.012","volume":"16","author":"Giacomelli","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2018.12.008_bb0085","article-title":"Efficacy and safety of belimumab in primary Sjogren's syndrome: results of the BELISS open-label phase II study","author":"Mariette","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2018.12.008_bb0090","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1136\/annrheumdis-2012-202071","article-title":"Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjogren's syndrome: data from a placebo-controlled clinical trial","volume":"72","author":"Pollard","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2018.12.008_bb0095","first-page":"490","article-title":"Sequential therapy with belimumab followed by rituximab in Sj\u00f6gren's syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy","volume":"32","author":"De Vita","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2018.12.008_bb0100","author":"St. Clair"},{"key":"10.1016\/j.autrev.2018.12.008_bb0105","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1136\/annrheumdis-2013-204653","article-title":"Abatacept treatment reduces disease activity in early primary Sj\u00f6gren's syndrome (open-label proof of concept ASAP study)","volume":"73","author":"Meiners","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2018.12.008_bb0110","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3109\/14397595.2014.951144","volume":"25","author":"Tsuboi","year":"2015","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.autrev.2018.12.008_bb0115","author":"Fischer"},{"key":"10.1016\/j.autrev.2018.12.008_bb0120","first-page":"5532","article-title":"Cytokine mRNA expression in salivary gland biopsies of Sj\u00f6gren's syndrome","volume":"152","author":"Fox","year":"1994","journal-title":"J Immunol Baltim Md"},{"key":"10.1016\/j.autrev.2018.12.008_bb0125","first-page":"131","article-title":"Tumor necrosis factor-alpha and receptors for it in labial salivary glands in Sj\u00f6gren's syndrome","volume":"19","author":"Koski","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2018.12.008_bb0130","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/art.20146","article-title":"Inefficacy of infliximab in primary Sj\u00f6gren's syndrome: results of the randomized, controlled trial of Remicade in primary Sj\u00f6gren's syndrome (TRIPSS)","volume":"50","author":"Mariette","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2018.12.008_bb0135","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1002\/art.20299","article-title":"Etanercept in Sj\u00f6gren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial","volume":"50","author":"Sankar","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2018.12.008_bb0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030123","article-title":"Interleukin-1 inhibition and fatigue in primary Sj\u00f6gren's syndrome--a double blind, randomised clinical trial","volume":"7","author":"Norheim","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2018.12.008_bb0145","first-page":"1089","article-title":"Salivary and serum interleukin 6 in primary Sj\u00f6gren's syndrome","volume":"24","author":"Grisius","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2018.12.008_bb0150","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1016\/S0161-6420(98)91236-2","article-title":"Elevated tear interleukin-6 levels in patients with Sj\u00f6gren syndrome","volume":"105","author":"Tishler","year":"1998","journal-title":"Ophthalmology"},{"key":"10.1016\/j.autrev.2018.12.008_bb0155","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.immuni.2008.11.014","article-title":"A low interleukin-2 receptor signaling threshold supports the development and homeostasis of T regulatory cells","volume":"30","author":"Yu","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.autrev.2018.12.008_bb0160","article-title":"Phosphatidylinositol-3-Kinase Delta pathway a novel therapeutic target for Sjogren's syndrome","author":"Nayar","year":"2019","journal-title":"ACR Meet Abstr"},{"key":"10.1016\/j.autrev.2018.12.008_bb0165","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00228-017-2205-7","article-title":"First-in-human studies of seletalisib, an orally bioavailable small-molecule PI3K\u03b4 inhibitor for the treatment of immune and inflammatory diseases","volume":"73","author":"Helmer","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.autrev.2018.12.008_bb0170","article-title":"The Jak-STAT pathway stimulated by interferon alpha or interferon beta","volume":"2004","author":"Horvath","year":"2004","journal-title":"Sci STKE Signal Transduct Knowl Environ"},{"key":"10.1016\/j.autrev.2018.12.008_bb0175","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s40262-015-0240-z","article-title":"Pharmacokinetics and pharmacokinetic\/pharmacodynamic modeling of filgotinib (GLPG0634), a selective JAK1 inhibitor, in support of phase IIB dose selection","volume":"54","author":"Namour","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.autrev.2018.12.008_bb0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0156063","article-title":"Dual role of the tyrosine kinase syk in regulation of toll-like receptor signaling in Plasmacytoid dendritic cells","volume":"11","author":"Aouar","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2018.12.008_bb0185","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/sji.12069","article-title":"Inhibitors of BTK and ITK: state of the new drugs for Cancer, autoimmunity and inflammatory diseases","volume":"78","author":"Vargas","year":"2013","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.autrev.2018.12.008_bb0190","doi-asserted-by":"crossref","first-page":"26502","DOI":"10.1074\/jbc.M116.743328","article-title":"Identification of Iguratimod as an inhibitor of macrophage migration inhibitory factor (MIF) with steroid-sparing potential","volume":"291","author":"Bloom","year":"2016","journal-title":"J Biol Chem"},{"key":"10.1016\/j.autrev.2018.12.008_bb0195","article-title":"Novel disease-modifying anti-rheumatic drug iguratimod suppresses chronic experimental autoimmune encephalomyelitis by down-regulating activation of macrophages\/microglia through an NF-\u03baB pathway","volume":"8","author":"Li","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.autrev.2018.12.008_bb0200","doi-asserted-by":"crossref","DOI":"10.1111\/sji.12649","article-title":"Expression of interleukin-17 in primary Sj\u00f6gren's syndrome and the correlation with disease severity: a systematic review and meta-analysis","volume":"87","author":"Zhang","year":"2018","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.autrev.2018.12.008_bb0205","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.0105-2896.2009.00867.x","article-title":"Signaling and ligand interaction of ILT7: receptor-mediated regulatory mechanisms for plasmacytoid dendritic cells","volume":"234","author":"Cao","year":"2010","journal-title":"Immunol Rev"},{"key":"10.1016\/j.autrev.2018.12.008_bb0210","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1177\/0961203316678675","article-title":"Safety, pharmacokinetics, and pharmacodynamics of RSLV-132, an RNase-fc fusion protein in systemic lupus erythematosus: a randomized, double-blind, placebo-controlled study","volume":"26","author":"Burge","year":"2017","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2018.12.008_bb0215","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1172\/JCI0214682","article-title":"Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity","volume":"110","author":"Saegusa","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2018.12.008_bb0220","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00806","article-title":"Pharmacodynamic monitoring of RO5459072, a small molecule inhibitor of Cathepsin S","volume":"8","author":"Theron","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2018.12.008_bb0225","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1136\/ard.2009.110619","article-title":"EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome","volume":"69","author":"Seror","year":"2010","journal-title":"Ann Rheum Dis"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997219300862?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997219300862?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:14:16Z","timestamp":1761599656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997219300862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S1568997219300862"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2018.12.008","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.735506719.793564241","asserted-by":"object"}]},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The pipeline of targeted therapies under clinical development for primary Sj\u00f6gren's syndrome: A systematic review of trials","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2018.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}